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This work focuses on P450 biosensors based on multiwalled carbon nanotubes (MWCNT) and differ-
ent cytochrome isoforms: 3A4, 2B4, 2C9. The proposed biosensors exhibit enhanced sensitivities and
decreased detection limits thanks to carbon nanotubes. The MWCNT structuring improves the sen-
sitivity from 5.1 to 20.5nA/mMmm2 in case of CYP2B4-mediated Benzphetamine detection, from
0.26 to 0.63nA/Mmm2 in case of CYP3A4-mediated Cyclophosphamide detection, and from 0.11 to
0.25nA/Mmm2 in case of CYP2C9-mediated Naproxen detection. By using MWCNT, the limit of detec-arbon nanotubes
ytochromes P450
rugs detection
ulti-drug detection
ersonalized therapy
tion was enhanced from 59 to 12M in case of Cyclophosphamide and from to 187 to 82M in case of
Naproxen. This makes possible the drug detection in human serum within the pharmacological range. In
the paper, a new mathematical model is also proposed to succeed in discriminating different drug contri-
butions in amixture containing both Cyclophosphamide andDextromethorphan or combining Naproxen
and Flurbiprofen. Data analysis shows variations in reduction peaks that are dependent on the drug ratio,
ith co
ay tand that are consistent w
detection and opens the w
. Introduction
The development of new technologies in personalized therapy
s required to increase the fraction of patients that can beneﬁt of
harmacological treatments. For many of the major pathologies,
he average rate of efﬁcacy of drug therapies ranges from 20% to
0% (Aspinall andHamermesh, 2007).Moreover, approximately 7%
f hospitalized patients experience serious adverse drug reactions
Lazarou et al., 1998). For this reason, drug therapy needs person-
lization to the individual patient (Daly, 2007; Turner et al., 2007).
ne of the reasons for this variability is genetic polymorphisms. For
xample, variations in cytochrome P450 2D6 (Frank et al., 2007), an
nzyme that accounts for the metabolism of 19% of known drugs
KashubaandBertino, 2003), causesoverdosing in “poormetaboliz-
rs” and underdosing in “ultrafastmetabolizers”. This classiﬁcation
ffects the bioavailability of the active compounds after a single
dministration, as demonstrated for Nortriptyline (Lin, 2007).
At present, theonly strategy forpersonalizing thedrug therapies
s to check the genetic predisposition of patients. The AmpliChip
YP450 (De Leon et al., 2006) is a genetic test based on microarray
echnology commercialized by Roche. It screens genetic mutations
n CYP2D6 and CYP2C19, yielding a classiﬁcation of patients in
oor, intermediate, extensive, and ultra-rapid metabolizers.
∗ Corresponding author. Tel.: +41 21 693 0915; fax: +41 21 693 0909.
E-mail address: sandro.carrara@epﬂ.ch (S. Carrara).
956-5663/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
oi:10.1016/j.bios.2011.03.009mpetitive kinetics of substrates. This new approach enables multiple drug
o possible applications in personalized therapy.
© 2011 Elsevier B.V. All rights reserved.
Although this technology represents a great improvement with
respect to the traditional approach, the sole knowledge of geno-
type is not sufﬁcient to achieve the maximum accuracy in drug
administration, since human metabolism may vary in short time
periods and it is related to patients’ nutrition, history, attitudes,
and environmental conditions.
Drug metabolism should be monitored on a daily basis to
optimize any ongoing drug therapy. However, therapeutic drug
monitoring, i.e., quantiﬁcation of drug concentrations after admin-
istration to see whether the desired concentration range has been
reached, is available only in large clinical chemistry labs, with
bulky and expensive equipment. A reliable low-cost technology
to monitor multiple drug compounds in patients for personalized
treatments at point-of-care can be developed using cytochromes
P450 as probe proteins. Biosensors based on individual P450 pro-
teins have already been proposed (Iwuoha et al., 2007; Joseph
et al., 2003; Liu et al., 2008); unfortunately, the detection sensi-
tivity achieved is often too far from the drug therapeutic ranges
for real applications in human serum. Recently it has been shown
howamajor improvement in P450 sensitivity can be obtained from
electrode nanostructuring, using materials like zirconium dioxide
(Peng et al., 2008), gold nano-particles (Shumyantseva et al., 2005),
or carbon nanotubes (Carrara et al., 2008).In this paper,we propose amulti-panel approach for developing
biosensors based on multiwalled carbon nanotubes (MWCNT) and
three different cytochrome P450 isoforms: the 3A4, 2B4, 2C9. The
paperpresents results indetectingdifferentdrugs:Benzphetamine,
a compound used in anti-obesity treatments; Cyclophosphamide,
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n anti-cancer agent; Dextromethorphan, a drug commonly used
s cough suppressant; Naproxen and Flurbiprofen, twowidespread
nti inﬂammatory compounds. The usage of MWCNT improves the
ensor sensitivity, reaching the range to discriminate the pres-
nce of drugs in human serum and within the pharmacological
ange. The measurement at different electrochemical potentials
mproves the speciﬁcity and supports the possibility of multiple
rug detection. In particular, different drug contributions in multi-
le detection are determined by ﬁtting the cyclic voltammograms
ith Gaussian decomposition and accounting for cross-interfering
orm different drug compounds on the same CYP protein. A new
odel is proposed for the right estimation of each Gaussian ampli-
ude. The results demonstrate that the reached sensitivity and
peciﬁcity are suitable for applications in personalized therapy and
pen the possibility to the realization of sensors for point-of-care
onitoring by patient’s even at home.
. Materials and methods
.1. Reagents
Carbon paste screen-printed electrodes (model DRP-110) were
urchased from Dropsens. Cytochrome P450 2B4 was isolated and
uriﬁed from the microsomal fraction of rabbit (Shumyantseva
t al., 2007). Cytochrome 2B4 and Benzphetamine substrates were
eceived from the Institute of Biomedical Chemistry of the Rus-
ian Academy of Biomedical Science. Cytochrome P450 3A4 and
C9 microsomes were purchased from Sigma–Aldrich, and used
ithout further puriﬁcation. Cyclophosphamide (CP) and Dex-
romethorphan (DX) was purchased from Sigma and diluted in
BS 100mM pH 7.4 to the working concentrations. Naproxen (NP)
nd Flurbiprofen (FB) was purchased from Sigma and diluted in
thanol to the working concentrations. Multi walled carbon nan-
tubes (MWCNT – diameter 10nm, length 1–2m, COOH content
%)were purchased in powder (95% purity) fromDropSens (Spain),
iluted in chloroform to the concentration of 1mg/ml, and then
onicated for 20min in order to break macro-aggregates. Human
erum was purchased from Lonza and used without any dilution.
.2. Electrode preparation
The screen-printed electrodes were purchased from DropSens,
pain. They were fabricated with of a graphite or a gold working
lectrode, a graphite or a platinum counter electrode and a sil-
er reference electrode. The working electrode area is 12.56mm2
hile the total area of the cell is 22mm2. CNT nano-structuring
as obtained by gradually dropping 30l of CNT solution onto
he working electrode and waiting until complete evaporation of
he chloroform. Electrode functionalization was obtained by drop
asting P450 solutions onto the working electrode and incubation
t 4 ◦C overnight. The excess of cytochrome was then removed by
ashing with milliQ water.
.3. SEM measurement
Morphological analysis of the structured and functionalized
lectrodes was done using a Scanning Electron Microscope (SEM).
Zeiss SUPRA 40 SEM instrument was used to acquire images for
are, CNT-structured and P450-functionalized electrodes. Images
ere acquired in the 5–20kV range..4. Size analysis on SEM images
TheprogramImageJ (Abramoff et al., 2004)wasused to calculate
he average diameters and the standard deviations for the ﬁbers
ecognized in the SEM images. To analyze the obtained results,ctronics 26 (2011) 3914–3919 3915
Monte Carlo method (Hammersley and Handscomb, 1975) was
used to simulate proteins deposition on carbon nanotubes. The
P450 proteins are globular proteins, and their 3-D structure may
be included in a sphere of 8nm (Locuson and Tracy, 2006), as con-
ﬁrmed by direct AFM imaging on P450 samples (Kiselyova et al.,
1999). Although the different isoforms of the P450 cytochrome
exhibit similar sizes, we need to take into account a more pre-
cise estimation for the protein diameter. Therefore, the Crystal
3-D structure of the human microsomal P450 3A4 presents in
the protein RCSB Protein Data Bank (Yano et al., 2004) was used
as model to precisely estimate the average diameter of the pro-
tein in a random orientation. Different carbon nanotube diameters
were randomly selected among those measured in SEM images
of non-functionalized samples. Then, 10,000 depositions onto car-
bon nanotubes of proteins in random orientation where simulated
in order to estimate the ﬁnal average diameter reached by the
ﬁber.
2.5. Electrochemical measurement
The electrochemical response of the biosensor was investigated
with cyclic voltammetry under aerobic conditions. Voltammo-
grams were acquired using a Versastat 3 potentiostat (Princeton
Applied Technologies). The electrode was covered with 100l of
PBS 10× at pH 7.4, or serum. Drug samples were added in drops
of 1l. The cyclic voltammograms were acquired with potential
sweeps between −600 and +300mV vs. Ag/AgCl at a scan rate of
20mV/s. Peak current values were then extracted according to the
procedure reported in (Carrara et al., 2009).
3. Results and discussion
3.1. AFM imaging
Fig. 1A shows bundles ofMWCNT cast onto carbon paste screen-
printed electrodes. The nanotubes are randomly organized in a
net that greatly increases the surface available for the protein
adsorption. Fig. 1B shows that the apparent thickness of the carbon
nanotubes increases after the probe immobilization. A direct com-
parison of the apparent ﬁber sizes in SEM images is used to show
that no more than one protein layer surrounds the single carbon
nanotube. Indeed, size analysis performed on different SEM images
shows that this increase goes from 11.14±2.59nm, in case non-
functionalized MWCNT, to 19.51±5.72nm, in case of the MWCNT
functionalized with microsomes containing the protein P450 3A4.
Simulated depositions done by using the Monte Carlo method
return a ﬁnal diameter for a single layer of P450 3A4 proteins
surrounding the carbon nanotube equal to 21.71±2.78nm. The
average diameter obtained from SEM measurements does not sta-
tistically differ from that obtained from Monte Carlo simulations.
Therefore, we can conclude that a single layer of probe proteins is
surrounding each single nanotube ﬁber. Taking into account that
the 3A4 proteins are dispersed onto the carbon nanotubes when
they are embedded in microsomes, a ﬁber diameter that is much
smaller than that of a typical microsome means that the carbon
nanotubebreaks themicrosome. Thus, the P450probes are indirect
contact with the tube surface. Consequently, even with samples of
P450 probes embedded in microsomes, carbon nanotubes assure
a direct electron-transfer to the P450 proteins, as obtained in the
past with other P450 isoforms immobilized after protein puriﬁca-
tion (Carrara et al., 2008). On the other hands, the average diameter
is larger in the simulations than that measured in the SEM images.
Moreover, the measure of its standard deviation in SEM images
is larger than that theoretically estimated. This means that other
components of the microsome (pieces of membrane, P450 reduc-
3916 S. Carrara et al. / Biosensors and Bioel
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y using multi-walled carbon nanotubes (A) and after immobilization with P450
A4 proteins (B).
ases, etc.) may also contribute to the bio-layer coating the carbon
anotube..2. Improved detection limit
We registered an improved sensitivity during drug detection
sing cytochromes adsorbed onto carbon nanotubes. Fig. 2 shows
wo calibration curves estimated from Faradic current peaks mea-
ig. 2. Calibration curves in detection of Cyclophosphamide (CP) from peak cur-
ents as registered in cyclic voltammograms acquired with P450 3A4 immobilized
nto screen-printed electrodes with or without multi walled carbon nanotubes.
he voltammograms were acquired with the drug dissolved in PBS and at the scan
elocity of 20mV/s.ectronics 26 (2011) 3914–3919
sured with cyclic voltammetry. These calibrations show current
increase in presence of increasing drug amounts. The ﬁgure clearly
shows that the detection limit obtained in the case of the P450
immobilized onto bare screen-printed electrodes is close to 75M.
This is not enough because the range of concentration found
in patients’ serum (the so called “therapeutic range”) for the
Cyclophospamide is from 2.6M to 76.6M (Juma et al., 1979). On
the other hand, Fig. 2 shows that MWCNT are deﬁnitely required
to ﬁt the required concentrations window.
The enhancement provided by carbon nanotubes is crucial to
realize biosensors for drugmonitoring. One of the biggest obstacles
to overcome in drug detection is the capability to sense com-
pounds in serum with concentrations ranging typically in the
order of M or nM. Most of P450-based biosensors proposed in
literature demonstrate detection windows in the mM scale. For
example, P450 detection of Verapamil is shown for concentrations
of 0.5–3mM (Joseph et al., 2003), which is orders of magni-
tude higher then its pharmacological range, typically below 55nM
(Eichelbaum et al., 1981). Similarly, detection of Benzphetamine is
listed in Table 1 of Supplementary Files (published online) in the
range 0.5–4mM, which is not suitable for real applications since
the amphetamine level in human blood is below 74nM (Schepers
et al., 2003).
Inorder to compareourdetection limits reachedbyusing carbon
nanotubes with concentration levels in human blood, more pre-
cisely estimations were done by considering the IUPAC deﬁnition
(Mc Naught and Wilkinson, 1997):
L.O.D. = kıi
S
(1)
where L.O.D. is the limit of detection, ıi is the standard deviation of
theblankmeasures,S is thedetector sensitivity, andk is aparameter
accounting for the conﬁdence level (k=1, 2, or 3 corresponds to
68.2%, 95.4%, or 99.6% of statistical conﬁdence). The background
has been subtracted before the computation of the L.O.D. with Eq.
(1) because it is only due to double-layering phenomenon related
to carbon nanotubes (Carrara et al., 2005) and it is not related to
the drugs detection as performed by the P450 cytochromes.
In the case of the Cyclophospamide, the detection limit from
deﬁnition (1) goes down from 59M to 12M, once the protein
is immobilized onto MWCNT. The improved L.O.D ﬁts quite well
with a concentration level in patients below 76.6M (Juma et al.,
1979). Similarly, we got improvement from 187 to 82M in the
case of Naproxen detected with the protein P450 2C9 immobilized
into MWCNT. Even in this case, the improved L.O.D. ﬁts better with
the concentration level in patients, which range from 21 to 515M
(Korzekwa et al., 1998).
Fig. 3 shows that we also obtained similar results in the detec-
tion of Cyclophosphamide in human serum. Using the P450 3A4
on MWCNT, the detection limit reached in serum was at 33M,
according to deﬁnition (1). This detection limit ﬁts quite well
with windows of concentration of Cyclophosphamide found in
patients’ plasma for some applications, which varies between 3.8
and 157M (Struck et al., 1987). Thus, our result shows that drug
detection is also possible in human serum when the CYP pro-
teins are immobilized onto carbon nanotubes, because they ensure
higher sensitivity and lead to lower detection limits.
Table 1 of the Supplementary Files (published on line)
summarizes the sensitivity enhancements we obtained after
immobilizing different P450 proteins on MWCNT. The sensi-
tivity in case of CYP2B4-mediated detection of benzphetamine
increases from 5.1nA/mMmm2 to 20.5nA/mMmm2. The sensitiv-
ity for CYP3A4-mediated detection of Cyclophosphamide increases
from 0.26 to 0.63nA/mMmm2, and that for Naproxen from 0.11
to 0.25nA/mMmm2. Similar sensitivity enhancement has been
recently obtained using MWCNT for hydrogen peroxide based
S. Carrara et al. / Biosensors and Bioele
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erum and at the scan velocity of 20mV/s.
etection. In that case, a sensitivity gain up to seven times has been
egistered (Boero et al., 2009).
.3. A new approach to improve speciﬁcity
Another crucial aspect in the P450 biosensor development is its
peciﬁcity. Multi-component Faradic currents are measured when
drug cocktail is present in the blood. Every cytochrome iso-
orm is capable to metabolize a broad range of compounds. For
xample, the CYP2C9 may sense Torsemide, as well as Diclofenac,
olbutamide, S-Warfarin, andSulfaphenazole (Johnsonet al., 2005).
evertheless, it is also well known that, often, different Faradic
urrents in cyclic voltammograms are shifted towards different
otentials. On CYP2C9, Torsemide presents a current peak at the
otential of −19mV, while Diclofenac exhibits a current maximum
t −41mV (Johnson et al., 2005). The Figure reported in the Supple-
entary Files (published online) conﬁrms this feature of the drug
lectrochemical signature: the plot shows that Cyclophosphamide
CP) is detected at −296mV, while Dextromethorphan (DX) at
392mV, conﬁrming that multiple drugs can be simultaneously
etected using a single cytochrome isoform.
In the case of multi-detection by means of single P450 protein,
e need to take into account cross-correlations between different
ompounds. Measures on the same amount of CP drug (400M)
epeated in presence of different amount of the DX (ranging from
to 400M) result in different registered currents for the Faradic
eak corresponding to CP in the cyclic voltammogram, as clearly
hown by Fig. 4. In particular, we observed smaller currents cor-
ig. 4. Cyclic voltammograms acquired with P450 3A4 immobilized onto multi
alled carbon nanotubes during the simultaneous detection of Cyclophosphamide
CP) and Dextromethorphan (DX), at different concentration of DX. The voltammo-
rams were acquired with the drugs dissolved in PBS and at the scan velocity of
0mV/s.ctronics 26 (2011) 3914–3919 3917
responding to the same amount of CP for increasing amounts of
DX. This is coherent with the phenomenon of inhibition already
observed in some cases of P450 enzymatic activity (Tracy, 2003).
Due to this phenomenon, the Faradic current related to detection
of the single drug component is not only related to the amount
of that drug. It is also affected by the concentrations of the other
interfering drugs present into the sample.
A general approach for a correct estimation of the drug amounts
in the sample is still possible by considering that the Faradic current
can be decomposed in Gaussian components:
i(V) =
∑
∀k
kCk
⎧⎨
⎩
∏
∀j /= k
Ak
(
Cj
)
⎫⎬
⎭ e
− (V−Vk)
2
k
2 (2)
where the term  k is deﬁned as:
k = 0.4463
(
n3F3vDk
RT
)1/2
A (3)
So, the ﬁnal current will be the sum of all the Gaussian contri-
butions of each single drug. Every single contribution will vary in
a dynamic manner, according to the concentration of all the speci-
men insolution.Coherentlywith theRandles-Sevcikequation (Bard
and Faulkner, 2001), Eqs. (2) and (3) account for the concentration
and diffusion coefﬁcients of each single drug (Ck and Dk). Vk are
the positions of each component, k are the component widths,
and the Ak(Cj) are the component amplitudes that also depend on
the concentration of all the other interfering drugs (Cj). The other
parameters in the Eqs. (2) and (3) are the usual ones of the Randles-
Sevcik equation: n is the number of electrons involved in the redox,
F is the faraday constant,  is the scan-rate of the voltammetry, A
is the electrochemical active area, R is the gas constant, T is the
temperature.
For the amplitude of these Faradic components, we need now
to take into account the kinetics of the P450/drug interactions
for the interfering compounds. For usual metabolic kinetics, the
enzymatic-inhibition of the detection on the drug compound
k from the interfering compound j will be mediated by the
Michaelis–Menten kinetics as:
Ak
(
Cj
)
= Ak0
(
1 − εjwj
)
(4)
The wj is the reaction rate of the interfering drugs that follows
the Michaelis–Menten equation (Naka and Sakamoto, 1992):
wj =
VmaxCj
KM + Cj
(5)
where Vmax and KM are the usual kinetic parameters for the max-
imal velocity and for the concentration of substrate at which
half-maximal velocity is achieved (Naka and Sakamoto, 1992). The
parameter Ak0 is the amplitude of the k-Gaussian, and Cj is the con-
centrations of the interfering drug. The newparameter εj takes into
account the interference strength, and it may have values in the
range from zero to unity.
Analogously, in the case of the simultaneous detection of the
Naproxen (NP) and the Flurbiprofen (FP), we registered increasing
Faradic currents corresponding to the same amount of FL (200M)
in the presence of increasing amounts of NP (from 0 to 500M), as
clearly shown by Fig. 5. Even in this case, the observed increasing in
current is coherent with the phenomenon of enzymatic-activation
observed in some cases of P450 enzymatic activity (Tracy, 2003). In
this case, the amplitude of the Faradic components becomes:Ak
(
Cj
)
= Ak0
(
1 + εjwj
)
(6)
Eq. (6) differs from Eq. (4) only with the sign in front of the
Michaelis–Menten term. The Michaelis–Menten Eq. (5) is used to
enhance the Faradic current in Eq. (6), while it is used to depress
3918 S. Carrara et al. / Biosensors and Bioel
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alled carbon nanotubes during the simultaneous detection of Naproxen (NP)
nd Flurbiprofen (FL), at different concentration of NP. The voltammograms were
cquired with the drugs dissolved in PBS and at the scan velocity of 20mV/s.
he Faradic current in Eq. (4). So, the Eq. (6) may be used to analyze
he data contained in Fig. 5, where the Naproxen (NP) interferes by
nhancing the current related to the Flurbiprofen (FL) detection.
q. (4) may be instead used to analyze the data contained in Fig. 4,
here the Dextromethorphan (DX) interferes by depressing the
urrent related to the Cyclophosphamide (CP) detection.
More in general, different drugs may follow atypical kinetics
nsteadMichaelis–Mentenone.On thecytochromes2C9, Flurbipro-
en follows Michaelis–Menten kinetics, while Naproxen ﬁts better
ith the biphasic model, Dapson with sigmoidal model, and Pirox-
cam with substrate partial-inhibition (Tracy, 2003). So, we need to
eneralize the Eqs. (4) and (6) in order to account for other kinetics.
n case of the enzymatic-inhibition, we can write:
k
(
Cj
)
= Ak0
{
1 − εj˚ (x1, x2, x3, ...xn)
}
(7)
here ˚ is the model-function that generalizes for different kinet-
cs involved by the interfering drugs. This function ˚ depends on
ifferent parameters:
x1, x2, x3, ...xn) =
(
Cj, Vmax,j, KM,j, CLint1,j, CLint2,j, . . .
)
(8)
which are the drug concentration, maximal velocity, concen-
ration for achieving half-maximal velocity, but also depends by
arameters likeCLint1 andCLint2,whichare the intrinsic clearances
sually considered in atypical pharmacokinetics (Tracy, 2003).
f course, other parameters may be introduced in the Eq. (8),
epending on the kind of atypical kinetics is followed by the inter-
ering compound. In the case of enzymatic-activation, the Eq. (7)
ecomes:
k
(
Cj
)
= Ak0
{
1 + εj˚ (x1, x2, x3, ...xn)
}
(9)
Eqs. (2), (3), (7) and (9) show that the right identiﬁcation and
uantiﬁcation of each single drug in the electrochemical signa-
ure as registered by the cyclic voltammograms may be not so
rivial, while Eqs. (4)–(6) give the simpliﬁed model in case of com-
ounds following the Michaelis–Menten kinetics. In any case, the
evelopment of potentiostats, on either printed circuit board and
n-chip, enabling the acquisition of full voltammograms as well as
he automatic data analysis with Gaussian decomposition is deﬁ-
itely required to succeed in applications for personalized therapy
n monitoring the patients’ metabolism on drugs.
. ConclusionsIn this work, we developed high-sensitive biosensors support-
ng multi-panel detection to provide information on multi-drug
etabolism in human serum. Different P450 isoforms were immo-
ilized on multi-walled carbon nanotubes in order to improve
ensor sensitivity. Drug detection and relative performance wereectronics 26 (2011) 3914–3919
shown for Benzphetamine, Cyclophosphamide, Dextromethor-
phan, Naproxen, and Flurbiprofen.
The sensor proved, in case of Cyclophosphamide and Naproxen,
to be able to measure drug amounts comparable to the ones found
in patients during standard therapeutic regime.Moreover, we have
been able to perform Cyclophopshamide measurements into its
therapeutic range in undiluted human serum. These results prove
to be suitable for measurements in patients and, consequently, the
proposed approach can be used in personalized therapies.
The proposed technology also enables the identiﬁcation of
different drugs, as directly demonstrated for the simultane-
ous detection of Cyclophosphamide and Dextromethorphan with
CYP3A4 and the simultaneous detection of Naproxen and Flur-
biprofen with CYP2C9. An improved version of the Randles-Sevcik
equation that accounts fordrug interactions andadescriptionof the
effect of multiple drugs in the ﬁnal current peak based on Gaussian
analysis have been proposed.
In conclusion, the proposed sensors provide an innovative solu-
tion for point-of-care monitoring in the personalization of drug
therapies, as well as in pharmacokinetic studies in both animals
and humans. Since some pharmacokinetic studies are sequential,
an optimal use of this technology can accelerate drug development
by several months, saving great amounts of money.
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